Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia.

Gassem A GohalIbrahim Metaan GosadiBasheer Ahmed Cittana IqbalYahya H GhazwaniAmal M DaghririAhmad A ShugairiKhaled A DaghririAtyaf J ZurayyirAbdulrhman A NemriMonera A Abdulhaq

Published in: Patient preference and adherence (2022)

The findings indicate the importance of increasing the role of clinicians in educating patients and caregivers about the use of hydroxyurea and its benefits.

Keyphrases

saudi arabia
end stage renal disease
palliative care
ejection fraction
newly diagnosed
chronic kidney disease
sickle cell disease
prognostic factors